ACVR2B antibody (N-Term)

Catalog No. ABIN6295502

The Rabbit Polyclonal anti-ACVR2B antibody is suitable to detect ACVR2B in samples from Human and Mouse.

Quick Overview for ACVR2B antibody (N-Term) (ABIN6295502)

Target: ACVR2B (Activin A Receptor, Type IIB (ACVR2B))

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This ACVR2B antibody is un-conjugated

Application: Please inquire

Product Details anti-ACVR2B Antibody

Binding Specificity: N-Term

Purpose: Rabbit Anti-ACVR2B (N-term) Antibody

Immunogen: This ACVR2B antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected between aa 1 and 30 of human ACVR2B.

Application Details

Restrictions: For Research Use only

Handling

Storage: 4 °C,-20 °C

Storage Comment: 2-8°C (short-term), -20°C (long-term)

Target Details for ACVR2B

Target: ACVR2B (Activin A Receptor, Type IIB (ACVR2B))

Alternative Name: ACVR2B

Background:

Target Description: Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling, and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. ACVR2B (activin A type IIB receptor) displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor.

Gene Symbol: ACVR2B

Gene ID: 93

UniProt: Q13705

Pathways: Hormone Transport, Cancer Immune Checkpoints